Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis

INTRODUCTION: Pharmacoeconomic studies examining the cost-effectiveness of biological agents to treat moderate-to-severe psoriasis in real-life clinical practice are scarce. The aim of this study was to assess the efficiency, in terms of incremental cost-effectiveness, of etanercept and adalimumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruano, Juan, Isla-Tejera, Beatriz, Jiménez-Puya, Rafael, Rodriguez-Martin, Ana, Cárdenas, Manuel, Gómez, Francisco, Vélez, A. Antonio, del Prado-Llergo, José R., Moreno-Giménez, José C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889303/
https://www.ncbi.nlm.nih.gov/pubmed/24318413
http://dx.doi.org/10.1007/s13555-013-0030-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889303/
https://www.ncbi.nlm.nih.gov/pubmed/24318413
http://dx.doi.org/10.1007/s13555-013-0030-1

Ejemplares similares